Blueprint Medicines presents long-term AYVAKIT® benefits in indolent and advanced systemic mastocytosis at ASH 2025. Blueprint Medicines, a Sanofi company, today announced updated data reinforcing the clinical efficacy and safety of long-term AYVAKIT® (avapritinib) use across the spectrum of systemic mastocytosis (SM),…
Zoetis Secures Health Canada Approval for Portela™ (relfovetmab Injection) to Relieve Osteoarthritis Pain in Cats Zoetis Inc. today announced that Health Canada has approved Portela™ (relfovetmab injection) for the alleviation of pain associated with osteoarthritis (OA) in cats. Designed to provide three…
Merck Animal Health Secures FDA Conditional Approval for EXZOLT™ CATTLE-CA1—A Groundbreaking Tool Against New World Screwworm and Cattle Fever Tick Merck Animal Health, known globally as MSD Animal Health outside the United States and Canada and a division of Merck…
Alnylam Pharmaceuticals Announces Strategic Refresh of Board of Directors to Propel Next Phase of Growth Alnylam Pharmaceuticals, Inc.the global pioneer and leader in RNA interference (RNAi) therapeutics, today announced a significant strategic evolution of its Board of Directors, reflecting the…
BioNTech Secures Overwhelming Shareholder Support, Meets Minimum Condition to Complete CureVac Exchange Offer BioNTech SE announced today that it has successfully met the minimum tender condition for its exchange offer for all outstanding shares of CureVac N.V. According to official…
Johnson & Johnson and Naomi Watts Urge Women Over 40 to Embrace Eye Exams as a Foundational Act of Self-Care Johnson & Johnson Vision—a global leader in eye health—has joined forces with Academy Award–nominated actress, producer, entrepreneur, and women’s health…
Roche Launches Groundbreaking 15-Minute Point-of-Care Test for Whooping Cough and Other Bordetella Infections, Receiving FDA Clearance, CLIA Waiver, and CE Mark Roche has announced U.S. Food and Drug Administration (FDA) 510(k) clearance and Clinical Laboratory Improvement Amendments of 1988 (CLIA)…
Strand Therapeutics Strengthens Strategic Leadership with Appointment of Industry Veteran Jeb Keiper to Board of Directors Strand Therapeutics, a pioneering biotechnology company at the forefront of programmable mRNA therapeutics, has announced the appointment of Jeb Keiper as an independent member…
Cellares Appoints Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion and Drive Cell Therapy Access Cellares, the pioneering Integrated Development and Manufacturing Organization (IDMO) transforming the cell therapy landscape, today announced the appointment of Ali Soleymannezhad as…
Octave Bioscience Partners with Quest Diagnostics to Expand Nationwide Access to MSDA Test Octave Bioscience, a commercial-stage precision care company at the forefront of redefining disease management in multiple sclerosis (MS) and other neurodegenerative disorders such as Parkinson’s disease, today…
Omeros Corporation Announces Completion of Asset Purchase and License Agreement with Novo Nordisk for Zaltenibart a Late-Stage MASP-3 Inhibitor Omeros Corporation today announced the successful closing of its previously disclosed asset purchase and licensing transaction with Novo Nordisk, involving the…
Incyte Announces Appointment of Richard Hoffman as Executive Vice President and General Counsel Incyte today announced that Richard Hoffman has officially assumed the role of Executive Vice President and General Counsel, effective December 1, 2025. In this key leadership position,…